3rd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$370,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to raising awareness of Hepatitis C (no specific bills); H.R. 3293, H.R. 3288: FY 2010 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; H.R. 3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; S. 3711: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions.

LobbyistCovered position, as disclosed
JEREMY ALLEN —
AMIT K SACHDEV —

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA)

Bills named: S. 3711 (111th), H.R. 3293 (111th), H.R. 3288 (111th), H.R. 3974 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.